Cargando…
Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial
BACKGROUND: Depression is prevalent in people with type 2 diabetes and affects both glycemic control and overall quality of life. The aim of this trial was to evaluate the effect of the antidepressant paroxetine on metabolic control, quality of life and mental well-being in mildly depressed women wi...
Autores principales: | Paile-Hyvärinen, Maria, Wahlbeck, Kristian, Eriksson, Johan G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165418/ https://www.ncbi.nlm.nih.gov/pubmed/12747810 http://dx.doi.org/10.1186/1471-2296-4-7 |
Ejemplares similares
-
Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: A double-blind randomised placebo controlled 6-month trial
por: Paile-Hyvärinen, Maria, et al.
Publicado: (2007) -
Suicide attempts in clinical trials with paroxetine randomised against placebo
por: Aursnes, Ivar, et al.
Publicado: (2005) -
Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies
por: Carboni, Lucia, et al.
Publicado: (2019) -
Even more suicide attempts in clinical trials with paroxetine randomised against placebo
por: Aursnes, Ivar, et al.
Publicado: (2006) -
The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: A Meta-Analysis of Change on the Hamilton Rating Scales
por: Sugarman, Michael A., et al.
Publicado: (2014)